BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
See today's BioWorld
Home
» First phase III success for cell therapy in solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ESMO 2022
First phase III success for cell therapy in solid tumors
Sep. 8, 2022
By
Anette Breindl
No Comments
ESMO late breakers were released Sept. 8, and scientifically at least, a key theme of the meeting will be that cell therapies, at long last, are capable of besting solid tumors.
BioWorld
Clinical
Conferences
European Society for Medical Oncology
Cancer